|Bid||50.74 x 1300|
|Ask||51.00 x 1200|
|Day's Range||51.33 - 51.79|
|52 Week Range||37.62 - 52.94|
|Beta (5Y Monthly)||0.49|
|PE Ratio (TTM)||26.61|
|Forward Dividend & Yield||1.70 (3.29%)|
|Ex-Dividend Date||Apr 30, 2020|
|1y Target Est||58.38|
The coronavirus stock market rally had a strong week despite Thursday's fade. Teladoc lead new breakouts. What's next for Tesla after a blowout week?
Sanofi (SNY) and Regeneron discontinue U.S.-based phase III coronavirus study on Kevzara following failure to achieve improvement in hospitalized patients with severe COVID-19 patients of statistical significance.
Pfizer (PFE) releases promising early results from its COVID-19 vaccine study. Several new drug/line extensions get approval in the United States, EU and Japan.
Previous trial results had shown that the drug did not help patients with less severe COVID-19, the disease caused by the novel coronavirus, and shares of Regeneron fell about 3% in after hours trading. Other drugs in the same class, including Roche Holding AG's Actemra, are also being studied as treatments for COVID-19. Patients who required mechanical ventilation or high-flow oxygen therapy or treatment in an intensive care unit were considered critically ill.
Shares of Regeneron Pharmaceuticals Inc. were down 2.4% and Sanofi's stock declined 1.7% in after-hours trading on Friday after the companies halted a Phase 3 clinical trial testing their rheumatoid arthritis drug Kevzara as a COVID-19 treatment. The drug, which was being tested in 194 hospitalized COVID-19 patients receiving mechanical ventilation, did not meet the primary or key secondary endpoints in the study. The findings will be published in a peer-reviewed medical journal later this year. Sanofi is continuing to evaluate Kevzara using a different dose in a trial of COVID-19 patients taking place outside of the U.S. Since the start of the year, Regeneron's stock is up 65.7%, shares of Sanofi are up 2.6%, and the S&P 500 is down 3.5%.
The Food and Drug Administration’s new guidance document for developers of Covid-19 vaccines doesn’t spell out a timeline. SVB Leerink analyst Geoffrey Porges says the guidelines point firmly toward no vaccine being made available until next year.
Treatments for peanut allergy and Parkinson's disease are among U.S. drug launches that have been postponed by the COVID-19 pandemic as drugmakers struggle with disruptions to business, a Reuters review of filings and interviews with executives show. The Food and Drug Administration (FDA) has approved more than 30 new medicines since January, but at least five drugmakers including Bristol Myers Squibb, Sanofi , Neurocrine Biosciences, Endo Pharmaceuticals and Aimmune have changed their launch plans.
Spain's Pharma Mar is looking at listing on New York's Nasdaq market, joining a flurry of biotech companies aiming to tap investors' voracious appetite for the sector as it tests one of its therapies to treat COVID-19. The move comes several weeks after the company started mid-stage human trials of cancer drug Aplidin in COVID-19 patients.
Sanofi (SNY) closed at $51.08 in the latest trading session, marking a +0.33% move from the prior day.
Inovio Pharmaceuticals Inc. has yet to share results from the Phase 1 trial for its COVID-19 vaccine candidate, but has already received millions of dollars in funding to scale up manufacturing capacity.
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
French drugmaker Sanofi <SASY.PA>, which employs more than 100,000 people worldwide, confirmed on Friday it will axe up to 1,680 jobs in Europe to cut costs and lift profits. The lay-offs are part of a broader strategy outlined in December by Sanofi CEO Paul Hudson, which includes a cost savings target of 2 billion euros ($2.2 billion) by 2022. A Sanofi spokeswoman said the cuts, mainly affecting blue-collar workers, would be carried out over three years.
Sanofi <SASY.PA> is considering cutting hundreds of jobs and will discuss potential steps with staff representatives over the coming days, five sources said on Thursday, the latest move by the French drugmaker's chief executive Paul Hudson to cut costs. Management will meet staff representatives on Friday and Monday next week to outline a restructuring plan, five sources familiar with the matter told Reuters. The reorganisation could involve several European countries and possibly others outside the region, as well as all the divisions of Sanofi except the vaccines and rare diseases unit Genzyme, the sources said.
From deploying experts amid global travel restrictions to managing extreme storage conditions, and even inventing new kinds of vials and syringes for billions of doses, the path is strewn with formidable hurdles, according to Reuters interviews with more than a dozen vaccine developers and their backers. Any hitch in an untested supply chain - which could stretch from Pune in India to England's Oxford and Baltimore in the United States - could torpedo or delay the complex process. Col. Nelson Michael, director of the U.S. Army's Center for Infectious Disease Research who is working on the government's "Warp Speed" project to deliver a vaccine at scale by January, said companies usually have years to figure this stuff out.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.
Translate Bio (TBIO) and Sanofi expand their tie-up to develop mRNA vaccines for infectious diseases. The deal boosts the company's cash resources significantly along with potential future revenues.
Stock extended gains Tuesday morning and the Nasdaq Composite hit a fresh record high as hopes for a coronavirus vaccine rose and U.S.-China trade fears dissipated.
On Tuesday, Dr. Fauci and other health officials testified before the U.S. House Energy and Commerce Committee to discuss how the administration has been handling the coronavirus outbreak. Yahoo Finance’s Anjalee Khemlani breaks down the latest news about the coronavirus on The Final Round.
New coronavirus cases are showing an alarming increase in the U.S., with more than half the states reporting numbers that are trending higher as the death toll topped 120,000, while President Donald Trump doubled down on his logic that the increases are just a result of more testing.
Sanofi SA (NASDAQ: SNY), which is in the race to develop a vaccine for SARS-CoV-2, which causes COVID-19, is unveiling an accelerated timeline for the vaccine program it is pursuing with GlaxoSmithKline plc (NYSE: GSK).Sanofi has also expanded its collaboration with mRNA vaccine company Translate Bio Inc (NASDAQ: TBIO).Sanofi Moves Up Vaccine Rollout Timeline: Sanofi said it expects to begin a Phase 1/2 study of the recombinant protein vaccine candidate it is co-developing with GlaxoSmithKline in September, and full approval is likely to be obtained at the earliest by the first half of 2021, the company said at its Virtual R&D Investor Day.GlaxoSmithKline is contributing its adjuvant AS03.In mid-April, when the companies announced the collaboration, they gave a timeline of the second half of 2021 for the probable commercial launch of the vaccine."Sanofi is advancing the only vaccine in the race that's off a proven platform that works at scale," Fierce Pharma reported, quoting Sanofi CEO Paul Hudson.Hudson expressed skepticism regarding the efficacy and the ability to scale manufacturing of the new breed of vaccines being developed by frontrunners working on the coronavirus. Translate Bio Pact: Sanofi is also strengthening its vaccine partnership with Translate Bio.The proposed expanded relationship is a collaboration and licensing agreement with the smaller biopharma to develop mRNA vaccines for infectious diseases, including COVID-19.Sanofi and Translate Bio are in the process of shortlisting a coronavirus mRNA vaccine candidate from animal studies and intend to start human trials in the fourth quarter of 2020.SNY Price Action: At last check, Sanofi shares were up 0.53% at $52.78.Related Links:The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout See more from Benzinga * The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout * The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Sanofi (SNY) and Translate Bio expand their tie-up to develop mRNA vaccines for infectious diseases. The companies are already developing a mRNA vaccine candidate to combat COVID-19.
The Translate Bio/Sanofi vaccine against Covid—using messenger RNA technology—could start human trials by this year’s fourth quarter.
Wall Street's main indexes were set to rise on Tuesday as investors took heart from reassurances that the Phase 1 trade agreement with China was intact, while upbeat business activity data from Europe boded well for U.S. surveys due later. "The China Trade Deal is fully intact," President Donald Trump tweeted late on Monday after White House adviser Peter Navarro sparked confusion by saying the deal was over, roiling risk assets globally and sending S&P stock futures down as much as 1.7%. A boost from technology stocks helped Wall Street's three major indexes close higher on Monday, with the tech-heavy Nasdaq registering its fourth record closing high this month.